This webinar will focus on the flexible approaches employed by Samsung Biologics’ CDO to achieve success for the partners, and highlight the significance of cell line development in partner molecule journeys and the importance of developability assessments for sequence selection.
Topics will include various proprietary platform processes utilized for the accelerated delivery while ensuring success. The panels will explain how the various proprietary platforms and in-house expertise align, and introduce the comprehensive options to align with the development strategies that partners want to follow based on project objectives.
During the webinar, the panels will introduce one of the successful cases of the cell line replacements with titer improvement, maintaining quality in USP and DSP.
Learning Objective 1
A case study: Cell line replacement to improve productivity
Learning Objective 2
Optimized solutions by utilizing novel in-house platforms